Blog
Is Our Short List a Reflection of Comfort or of the Market?
In nearly every executive search conversation I have with founders, CEOs, and board members in Life Sciences, there is an understandable instinct that surfaces early. “We already know who we would ...
What happens when everyone in the executive team is a specialist?
A life sciences company can have an impressive executive team on paper and still struggle to make good decisions. The Chief Scientific Officer understands the science. The Chief Medical Officer ...
The most expensive executive hire may be the one everyone agreed on
There is a particular moment in an executive search when everything appears to line up. The candidate has the right experience. The résumé makes sense. The references are strong. The ...
Do Public Biotech Companies in Major Indices Pay Executives More?
Do Public Biotech Companies in Major Indices Pay Executives More? We expected the answer to be yes. Public biotech companies included in major indices such as XBI, IBB, and NBI ...
The executive who was perfect for the last five years may be wrong for the next five
A successful executive hire creates a natural temptation to stop questioning the appointment. The company grows. The executive delivers. The board gains confidence. The leadership team develops a rhythm. Years ...
Why your next great life sciences leader may not look like your last one
For decades, life sciences companies have had a relatively familiar idea of what a senior executive should look like. A scientist with decades of industry experience. A commercial leader who ...
The Dual-Role Biotech Executive: Why Finance Sits at the Center of Role Consolidation
Executive leadership structures in public biotech are not always as neatly separated as an organizational chart might suggest. GeneCoda® analyzed the latest usable executive compensation disclosures across 393 active public ...
When a company’s success starts working against it
Problems invite scrutiny. Success can suppress it. When a life sciences company misses a clinical milestone, loses funding, or struggles to recruit talent, leadership teams immediately begin looking for the ...
The key-person problem – when one executive knows too much
A life sciences company can look remarkably healthy from the outside while carrying a significant organizational risk inside: too much of what matters sits with one person. It might be ...
